Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
Request a demo device
Help your patients try the Ellipta device by ordering a demo device
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long acting β2-agonist (LABA) or a combination of a LABA and a long-acting muscarinic antagonist (LAMA)3.
We are here to support
The burden of COPD
There are around 1.4 million GP consultations per year due to COPD, and it is the second largest cause of emergency hospital admissions in the UK4
Approximately 69% of patients with COPD receiving multiple-inhaler triple therapy are juggling multiple device types5
Are you familiar with NICE and GOLD recommendations for your COPD patients who are not adequately controlled?
GOLD and NICE recommend classes of medicines, not specific products
Link leads to GSK adaptation of NICE COPD guidelines (2019) and the GOLD strategy report (2025)4,6
The most frequently reported adverse reactions observed with Trelegy Ellipta, as reported in the Summary of Product Characteristics, are nasopharyngitis (7%), headache (5%) and upper respiratory tract infection (2%). Other common adverse reactions include: pneumonia, bronchitis, pharyngitis, rhinitis, sinusitis, influenza, candidiasis of mouth and throat, urinary tract infection, cough, oropharyngeal pain, constipation, arthralgia, back pain. In common with other ICS- containing medicines, there is an increased risk of pneumonia. Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of such infections overlap with the symptoms of COPD exacerbations. Risk factors for pneumonia in patients with COPD include current smoking, older age, low body mass index (BMI) and severe COPD.
Trelegy Ellipta should be used with caution in patients with unstable or life-threatening cardiovascular disease. Administration of fluticasone furoate/umeclidinium/vilanterol may produce paradoxical bronchospasm with an immediate wheezing and shortness of breath after dosing and may be life-threatening. If paradoxical bronchospasm occurs, treatment should be discontinued immediately. The patient should be assessed and alternative therapy instituted if necessary.
This list is not exhaustive, please consult the SmPC for more information3
Abbreviations
NICE, National Institute for Health and Care Excellence; GOLD, Global Initiative for Chronic Obstructive Lung Disease.
References
- Van der Palen J; NPJ Primary Care Respiratory Medicine;2016;26:16079;1-8
- Riley JH et al; International journal of chronic obstructive pulmonary disease;2016;11;1873-1880
- Trelegy Ellipta, Summary of product characteristics.
- COPD in over 16s: diagnosis and management NICE guideline [NG115]. Last updated: July 2019.
- IQVIA Triple Dynamic Prescribing (DRx), March 2025, commissioned by GSK.
- GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD. 2025 Report. https://goldcopd.org/2025-gold-report.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to GSK on 0800 221 441 or UKSafety@gsk.com.
September 2025 | PM-GB-FVU-WCNT-240024 (V2.0)
